1482 S.H. Madsen et al. / Steroids 76 (2011) 1474–1482 [23] Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H. Biphasic glucocorticoiddependent regulation <strong>of</strong> Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int 2009;85(6):538–45. [24] Buttgereit F, Zhou H, Kalak R, Gaber T, Spies CM, Huscher D, et al. Transgenic disruption <strong>of</strong> glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. Arthritis Rheum 2009;60(7):1998–2007. [25] Zalavras C, Shah S, Birnbaum MJ, Frenkel B. Role <strong>of</strong> apoptosis in glucocorticoidinduced osteoporosis and osteonecrosis. Crit Rev Eukaryot Gene Expr 2003;13(2–4):221–35. [26] Kerachian MA, Seguin C, Harvey EJ. Glucocorticoids in osteonecrosis <strong>of</strong> the femoral head: a new understanding <strong>of</strong> the mechanisms <strong>of</strong> action. J Steroid Biochem Mol Biol 2009;114(3–5):121–8. [27] Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, et al. Should <strong>subchondral</strong> <strong>bone</strong> turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 2008;16(6):638–46. [28] Kwan TS, Lajeunesse D, Pelletier JP, Martel-Pelletier J. Targeting <strong>subchondral</strong> <strong>bone</strong> for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2010;24(1):51–70. [29] Madsen SH, Goettrup AS, Thomsen G, Christensen ST, Schultz N, Henriksen K, et al. Characterization <strong>of</strong> an ex vivo femoral head model assessed by markers <strong>of</strong> <strong>bone</strong> and cartilage turnover. Cartilage 2011;2(3):265–78. [30] Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC. Cartilage degradation is fully reversible in the presence <strong>of</strong> aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 2008;10(3):R63. [31] Sorensen MG, Henriksen K, Schaller S, Henriksen DB, Nielsen FC, Dziegiel MH, et al. Characterization <strong>of</strong> osteoclasts derived from CD14 + monocytes isolated from peripheral blood. J Bone Miner Metab 2007;25(1):36–45. [32] Ghosh-Choudhury N, Windle JJ, Koop BA, Harris MA, Guerrero DL, Wozney JM, et al. Immortalized murine osteoblasts derived from BMP 2-T-antigen expressing transgenic mice. Endocrinology 1996;137(1):331–9. [33] Olsen AK, Sondergaard BC, Byrjalsen I, Tanko LB, Christiansen C, Muller A, et al. Anabolic and catabolic function <strong>of</strong> chondrocyte ex vivo is reflected by the metabolic processing <strong>of</strong> type II collagen. Osteoarthritis Cartilage 2007;15(3):335–42. [34] Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C, Henriksen K. Osteoclasts secrete non-<strong>bone</strong> derived signals that induce <strong>bone</strong> formation. Biochem Biophys Res Commun 2008;366(2):483–8. [35] Jonsson KB, Frost A, Larsson R, Ljunghall S, Ljunggren O. A new fluorometric assay for determination <strong>of</strong> osteoblastic proliferation: effects <strong>of</strong> glucocorticoids and insulin-like growth factor-I. Calcif Tissue Int 1997;60(1):30–6. [36] Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 2011;44(5-6):423–9. [37] Sumer EU, Sondergaard BC, Rousseau JC, Delmas PD, Fosang AJ, Karsdal MA, et al. MMP and non-MMP-mediated release <strong>of</strong> aggrecan and its fragments from articular cartilage: a comparative study <strong>of</strong> three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 2007;15(2):212–21. [38] Henriksen K, Gram J, Neutzsky-Wulff AV, Jensen VK, Dziegiel MH, Bollerslev J, et al. Characterization <strong>of</strong> acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7. Biochem Biophys Res Commun 2009;378(4):804–9. 76 [39] Camplejohn KL, Allard SA. Limitations <strong>of</strong> safranin ‘O’ staining in proteoglycandepleted cartilage demonstrated with monoclonal antibodies. Histochemistry 1988;89(2):185–8. [40] Habib GS. Systemic effects <strong>of</strong> intra-articular corticosteroids. Clin Rheumatol 2009;28(7):749–56. [41] Skwara A, Peterlein CD, Tibesku CO, Rosenbaum D, Fuchs-Winkelmann S. Changes <strong>of</strong> gait patterns and muscle activity after intraarticular treatment <strong>of</strong> patients with osteoarthritis <strong>of</strong> the knee: a prospective, randomised, doubleblind study. Knee 2009;16(6):466–72. [42] Mansell JP, Collins C, Bailey AJ. Bone, not cartilage, should be the major focus in osteoarthritis. Nat Clin Pract Rheumatol 2007;3(6):306–7. [43] van der Kraan PM, Vitters EL, Postma NS, Verbunt J, Van den Berg WB. Maintenance <strong>of</strong> the synthesis <strong>of</strong> large proteoglycans in anatomically intact murine articular cartilage by steroids and insulin-like growth factor I. Ann Rheum Dis 1993;52(10):734–41. [44] Madsen SH, Sumer EU, Bay-Jensen AC, Sondergaard BC, Qvist P, Karsdal MA. Aggrecanase- and matrix metalloproteinase-mediated aggrecan degradation is associated with different molecular characteristics <strong>of</strong> aggrecan and separated in time ex vivo. Biomarkers 2010;15(3):266–76. [45] Augustine AJ, Oleksyszyn J. Glucocorticosteroids inhibit degradation in bovine cartilage explants stimulated with concomitant plasminogen and interleukin- 1 alpha. Inflamm Res 1997;46(2):60–4. [46] Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, et al. Glucocorticoids suppress <strong>bone</strong> formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 2010;11(6):517–31. [47] Kalak R, Zhou H, Street J, Day RE, Modzelewski JR, Spies CM, et al. Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal <strong>bone</strong> structure in mice. Bone 2009;45(1):61–7. [48] Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC. Intermittent parathyroid hormone administration counteracts the adverse effects <strong>of</strong> glucocorticoids on osteoblast and osteocyte viability, <strong>bone</strong> formation, and strength in mice. Endocrinology 2010;151(6):2641–9. [49] Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local communication on and within <strong>bone</strong> controls <strong>bone</strong> remodeling. Bone 2009;44(6):1026–33. [50] Jevon M, Hirayama T, Brown MA, Wass JA, Sabokbar A, Ostelere S, et al. Osteoclast formation from circulating precursors in osteoporosis. Scand J Rheumatol 2003;32(2):95–100. [51] Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming <strong>of</strong> osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 2003;278(45):44667–74. [52] Soe K, Delaisse JM. Glucocorticoids maintain human osteoclasts in the active mode <strong>of</strong> their resorption cycle. J Bone Miner Res 2010 [Epub ahead <strong>of</strong> print]. Ref Type: Generic.
CHAPTER 6 CHAPTER 6: PAPER III PAPER III ___________________________________________________________________________ Introductory remarks This manuscript focuses on the pathogenesis <strong>of</strong> cartilage, and evaluates the different proteolytic degradation processes for aggrecan, which vary <strong>between</strong> the OA-stages. It is <strong>important</strong> to understand the different degrading processes <strong>of</strong> aggrecan if we want to target the right proteases at a certain stage <strong>of</strong> disease. 77
Change language